ArticleOrphanet journal of rare diseases2026
Developing a rare disease registry for inherited metabolic disorders in Pakistan.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInherited metabolic disorders (IMDs) underrecognized and underreported in Pakistan because of fragmented data systems, limited surveillance, and constrained diagnostic resources. We aimed to establish a continuous registry for IMDs to generate structured epidemiological, clinical, and biochemical data in a genetically heterogeneous population with high rates of consanguinity.
methodsA single-center rare disease registry for IMDs was developed at the Biochemical Genetics Laboratory, Aga Khan University Hospital, Pakistan, and implemented between 2024 and March 2026 using retrospective consolidation of cases from January 2013 onward, followed by prospective real-time data capture. Demographic, clinical, and biochemical data were collected through structured case report forms and linked laboratory records. Registry performance was monitored using predefined indicators, including case volume, number of diagnostic categories, and data quality assessed through three audit cycles, 12 staff training rounds, and source verification procedures.
resultsThe registry included 3,880 unique cases from January 2013 to March 2026 and documented 59 distinct IMDs across all four provinces of Pakistan. Parental consanguinity was reported in 66.5% of cases (n = 2,584). The most frequently identified disorders were methylmalonic aciduria (n = 555), biotinidase deficiency (n = 287), and urea cycle disorders (n = 218). The final data dictionary comprised 14 categories and 384 common data elements. Quality control measures, including 12 training rounds and periodic audits, improved data accuracy and completeness from 60% to 96% to enable successful registry integration. Piloting data collection tools achieved > 90% completeness in demographic and clinical fields.
conclusionThis first registry for IMDs in Pakistan provides a structured, quality-assured epidemiological resource for defining the burden and spectrum of these disorders. The registry establishes a foundation for improved diagnosis, service planning, policy development, and future multicenter rare disease research. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42919323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.